Ventilator-associated pneumonia
Drug research and approvals for ventilator-associated pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 51 studies of ventilator-associated pneumonia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 51
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAPNCT07854730 · Not applicable · Al-Zaytoonah University of Jordan · starts Oct 5, 2026
- Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric…NCT07848165 · Not applicable · Tanta University · starts Jul 1, 2026
- ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaNCT07759934 · Phase 2 · Jiangsu Aosaikang Pharmaceutical Co., Ltd. · starts Mar 25, 2026
- Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)NCT07585604 · Not applicable · Hospital de Clinicas de Porto Alegre · starts May 20, 2026
- Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly PatientsNCT07551258 · Not reported · Hospital Universitari de Bellvitge · starts May 1, 2026
- Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired…NCT07512596 · Phase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · starts Jul 21, 2026
- B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP…NCT07436780 · Not reported · University Hospital, Limoges · starts Jan 12, 2026
- Effect of Acetylcysteine Inhalation on Incidence and Time to Develop Ventilator Associated Pneumonia in Critically Ill…NCT07409727 · Phase 4 · Cairo University · starts Mar 1, 2026
- Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic…NCT07403474 · Phase 4 · Centre Hospitalier Universitaire de Nīmes · starts Mar 27, 2026
Approved 2
Phase 3 10
- MeropenemBacterial penicillin-binding protein inhibitor
- TazobactamBacterial beta-lactamase TEM inhibitor
- AmikacinBacterial 70S ribosome inhibitor
- CilastatinRenal dipeptidase inhibitor
- PiperacillinBacterial penicillin-binding protein inhibitor
- ImipenemBacterial penicillin-binding protein inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
- ColistimethateCell membrane inhibitor
- CeftolozaneBacterial penicillin-binding protein inhibitor
- Taniborbactam
Phase 2 4
- VancomycinPeptidoglycan inhibitor
- ChlorhexidineCell membrane inhibitor
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- IclaprimBacterial dihydrofolate reductase inhibitor
Phase 1 or earlier 1
- GentamicinBacterial 70S ribosome inhibitor
How its trials ended
339 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 80 whose ending is known, 41% met their primary endpoint, 14% missed it and 45% stopped early.
- Completed, result not reported14242%
- Status unknown6018%
- Ongoing5717%
- Met its primary endpoint3310%
- Stopped: other or unclear206%
- Missed its primary endpoint113%
- Stopped: enrollment or feasibility51%
- Stopped: lack of efficacy41%
- Stopped: sponsor or business decision41%
- Stopped: funding31%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA